DC
ESPR

Deere & Company’s Esperion Therapeutics ESPR Stock Holding History

Deere & Company’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,101
Closed -$565K – 1017
2015
Q1 		$565K Sell
6,101
-6,170
-50% -$398K 0.03% 578
2014
Q4 		$496K Buy
+12,271
New +$376K 0.03% 613

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deere & Company's ESPR Position: Q2 2015 in Review

Deere & Company sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 6,101 shares — an estimated $565K sold.

Deere & Company first reported a position in ESPR in Q4 2014 and held it in 2 quarters. The position peaked at $565K in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

  • Deere & Company reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Deere & Company sold 6,101 Esperion Therapeutics shares in Q2 2015, an estimated $565K.
  • Deere & Company first reported a position in Esperion Therapeutics in Q4 2014 and held it in 2 quarters.
  • Deere & Company's Esperion Therapeutics position peaked at $565K in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Deere & Company's 13F filing for Q2 2015, filed 13 Aug 2015.